Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Other Non Operating Income (2020 - 2025)

Avalo Therapeutics filings provide 5 years of Other Non Operating Income readings, the most recent being -$3000.0 for Q3 2025.

  • On a quarterly basis, Other Non Operating Income rose 40.0% to -$3000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$13000.0, a 160.0% decrease, with the full-year FY2024 number at -$5000.0, up 88.1% from a year prior.
  • Other Non Operating Income hit -$3000.0 in Q3 2025 for Avalo Therapeutics, up from -$5000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of -$3000.0 in Q3 2025 to a low of -$40000.0 in Q2 2023.
  • Median Other Non Operating Income over the past 4 years was -$10000.0 (2021), compared with a mean of -$14500.0.
  • Biggest five-year swings in Other Non Operating Income: plummeted 178.95% in 2021 and later soared 70.59% in 2024.
  • Avalo Therapeutics' Other Non Operating Income stood at -$15000.0 in 2021, then dropped by 13.33% to -$17000.0 in 2023, then skyrocketed by 70.59% to -$5000.0 in 2024, then soared by 40.0% to -$3000.0 in 2025.
  • The last three reported values for Other Non Operating Income were -$3000.0 (Q3 2025), -$5000.0 (Q2 2025), and -$5000.0 (Q3 2024) per Business Quant data.